Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Ther ; 24(4): 697-706, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26865405

ABSTRACT

Glycogen storage disease type Ia (GSD Ia) is caused by glucose-6-phosphatase (G6Pase) deficiency in association with severe, life-threatening hypoglycemia that necessitates lifelong dietary therapy. Here we show that use of a zinc-finger nuclease (ZFN) targeted to the ROSA26 safe harbor locus and a ROSA26-targeting vector containing a G6PC donor transgene, both delivered with adeno-associated virus (AAV) vectors, markedly improved survival of G6Pase knockout (G6Pase-KO) mice compared with mice receiving the donor vector alone (P < 0.04). Furthermore, transgene integration has been confirmed by sequencing in the majority of the mice treated with both vectors. Targeted alleles were 4.6-fold more common in livers of mice with GSD Ia, as compared with normal littermates, at 8 months following vector administration (P < 0.02). This suggests a selective advantage for vector-transduced hepatocytes following ZFN-mediated integration of the G6Pase vector. A short-term experiment also showed that 3-month-old mice receiving the ZFN had significantly-improved biochemical correction, in comparison with mice that received the donor vector alone. These data suggest that the use of ZFNs to drive integration of G6Pase at a safe harbor locus might improve vector persistence and efficacy, and lower mortality in GSD Ia.


Subject(s)
Endonucleases/metabolism , Genetic Therapy/methods , Glucose-6-Phosphatase/genetics , Glycogen Storage Disease Type I/therapy , RNA, Untranslated/genetics , Animals , Disease Models, Animal , Endonucleases/chemistry , Genetic Vectors/administration & dosage , Glycogen Storage Disease Type I/genetics , Mice , Survival Analysis , Treatment Outcome , Zinc Fingers
2.
Mol Genet Metab ; 109(2): 161-70, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23623482

ABSTRACT

Glycogen Storage Disease type Ia (GSD-Ia) in humans frequently causes delayed bone maturation, decrease in final adult height, and decreased growth velocity. This study evaluates the pathogenesis of growth failure and the effect of gene therapy on growth in GSD-Ia affected dogs and mice. Here we found that homozygous G6pase (-/-) mice with GSD-Ia have normal growth hormone (GH) levels in response to hypoglycemia, decreased insulin-like growth factor (IGF) 1 levels, and attenuated weight gain following administration of GH. Expression of hepatic GH receptor and IGF 1 mRNAs and hepatic STAT5 (phospho Y694) protein levels are reduced prior to and after GH administration, indicating GH resistance. However, restoration of G6Pase expression in the liver by treatment with adeno-associated virus 8 pseudotyped vector expressing G6Pase (AAV2/8-G6Pase) corrected body weight, but failed to normalize plasma IGF 1 in G6pase (-/-) mice. Untreated G6pase (-/-) mice also demonstrated severe delay of growth plate ossification at 12 days of age; those treated with AAV2/8-G6Pase at 14 days of age demonstrated skeletal dysplasia and limb shortening when analyzed radiographically at 6 months of age, in spite of apparent metabolic correction. Moreover, gene therapy with AAV2/9-G6Pase only partially corrected growth in GSD-Ia affected dogs as detected by weight and bone measurements and serum IGF 1 concentrations were persistently low in treated dogs. We also found that heterozygous GSD-Ia carrier dogs had decreased serum IGF 1, adult body weights and bone dimensions compared to wild-type littermates. In sum, these findings suggest that growth failure in GSD-Ia results, at least in part, from hepatic GH resistance. In addition, gene therapy improved growth in addition to promoting long-term survival in dogs and mice with GSD-Ia.


Subject(s)
Genetic Therapy , Glucose-6-Phosphatase/genetics , Glycogen Storage Disease Type I/physiopathology , Animals , Bone and Bones/diagnostic imaging , Bone and Bones/pathology , Bone and Bones/physiopathology , Dogs , Female , Glycogen/metabolism , Glycogen Storage Disease Type I/blood , Glycogen Storage Disease Type I/therapy , Growth Hormone/blood , Insulin-Like Growth Factor I/metabolism , Lipid Metabolism , Liver/metabolism , Male , Mice , Mice, Knockout , Osteogenesis , Radiography
SELECTION OF CITATIONS
SEARCH DETAIL
...